Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 12,626 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period A Clear all
Completed Not applicable Interventional Results available

Assessment of Energy Balance

NCT01678885
View directory record Official record
Conditions
Caloric Intake and Energy Metabolism
Interventions
Digital Photography of Foods, doubly labeled water, IDEEA, low-calorie diet, Actical, Sensewear Armband
Behavioral · Other · Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 30, 2026, 10:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

NCT07298408
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies
Interventions
Cannabidiol (CBD) oral solution, Full-Spectrum CBD hemp extract oral solution, Placebo in MCT oil oral solution
Drug
Lead sponsor
Florida A&M University
Other
Eligibility
40 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Effects of White Potato Consumption on Measures of Cardiometabolic Health in Individuals With Type 2 Diabetes Mellitus

NCT04511325
View directory record Official record
Conditions
Type2 Diabetes, Cardiometabolic Syndrome, Arterial Stiffness, Overweight and Obesity
Interventions
Potato Regimen, Refined Grain Regimen
Other
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 30, 2026, 10:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tebentafusp-tebn With LDT in Metastatic UM

NCT06626516
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

NCT05646706
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of APX001 High-load and Low-load Tablets

NCT05491733
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
APX001, APX001A
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

NCT00140855
View directory record Official record
Conditions
Synovial Sarcoma
Interventions
ipilimumab
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
10 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Phase 2 Interventional

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

NCT00734435
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
zonisamide SR plus olanzapine, Placebo plus olanzapine
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
National City, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

NCT00392925
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate 360 mcg, metreleptin, placebo-pramlintide 600 uL, placebo-metreleptin 1 mL, Pramlintide acetate 180 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
DeLand, Florida • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Results available

Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial

NCT02169089
View directory record Official record
Conditions
Atherosclerosis
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
41 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Yoga to Reduce Chaos and Improve Preschooler Sleep

NCT06549868
View directory record Official record
Conditions
Sleep, Inadequate, Sleep
Interventions
Yoga-based bedtime routine
Behavioral
Lead sponsor
Emily Guseman
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

NCT01700387
View directory record Official record
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA, Topiramate, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Noom Coach for Bariatric Surgery

NCT03386006
View directory record Official record
Conditions
Obesity
Interventions
Noom Coach for Bariatric Health
Behavioral
Lead sponsor
Noom Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation

NCT00887432
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Cholecalciferol, Laboratory Biomarker Analysis, Patient Observation, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Dietary Supplement · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Effectiveness of Internet-Based Cognitive Behavioral Therapy for Treating Mothers With Depression

NCT00601393
View directory record Official record
Conditions
Depression
Interventions
Cognitive behavioral therapy (CBT), Treatment as usual (TAU)
Behavioral · Other
Lead sponsor
Oregon Research Institute
Other
Eligibility
Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

NCT05205447
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Itraconazole, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 30, 2026, 10:19 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Cannabichromene Safety in Rheumatoid Arthritis

NCT07087938
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Cannabichromene
Drug
Lead sponsor
Crystal Lederhos Smith
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2030
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 30, 2026, 10:19 AM EDT
Recruiting Phase 3 Interventional

A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

NCT07727538
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome
Interventions
Olezarsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Assessing the Effectiveness of Concurrent Peer Review for Patients With Cardiovascular Disease and Diabetes

NCT00508014
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Usual Care, Concurrent Peer Review visit
Other · Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 30, 2026, 10:19 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of Metformin on Muscle Health of Older Adults

NCT03107884
View directory record Official record
Conditions
Muscle Atrophy, Insulin Resistance
Interventions
Metformin (Bed Rest), Placebo (Bed Rest), Metformin (2 week run-in only), Placebo (2 week run-in only)
Drug
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT04569084
View directory record Official record
Conditions
ALS
Interventions
MT-1186, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Early Phase 1 Interventional

Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis

NCT02285738
View directory record Official record
Conditions
Solid Tumor, Cancer
Interventions
Aspirin, Simvastatin, Observation
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

Multisite Controlled Trial of Cocaine Vaccine

NCT00969878
View directory record Official record
Conditions
Cocaine Dependence
Interventions
TA-CD Vaccination, Placebo Injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 30, 2026, 10:19 AM EDT